Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Neoplasm
94%
Monoclonal Antibody
91%
Diseases
86%
Phase I Trials
84%
Idiopathic Thrombocytopenic Purpura
78%
Nonhodgkin Lymphoma
69%
Malignant Neoplasm
63%
Adverse Event
57%
Pharmacokinetics
57%
Clinical Trial
56%
Non Small Cell Lung Cancer
50%
Breast Cancer
48%
Carboplatin
48%
Overall Survival
48%
Solid Malignant Neoplasm
46%
Rituximab
44%
Cetuximab
41%
Eltrombopag
41%
Bevacizumab
41%
Iodine-131
39%
Docetaxel
39%
Maximum Tolerated Dose
38%
Progression Free Survival
37%
Phase II Trials
36%
Gemcitabine
35%
Paclitaxel
34%
Antitumor Activity
33%
Prostate Cancer
32%
Metastatic Breast Cancer
30%
Doxorubicin
29%
Metastatic Colorectal Cancer
27%
Placebo
27%
Receptor
26%
Castration Resistant Prostate Cancer
25%
Thrombocytopenia
21%
Subcutaneous Injection
21%
Neutropenia
20%
Metastatic Melanoma
20%
Edrecolomab
20%
Ibritumomab Tiuxetan
20%
Prednisone
20%
Combination Therapy
19%
Adenocarcinoma
19%
Carcinoembryonic Antigen
19%
Abiraterone Acetate
19%
Androgen
18%
Immunoglobulin
18%
Epidermal Growth Factor Receptor
18%
Digestive System Cancer
17%
Medicine and Dentistry
Breast Cancer
97%
Idiopathic Thrombocytopenic Purpura
62%
Neoplasm
47%
Platelet
39%
Malignant Neoplasm
37%
Eltrombopag
34%
Monoclonal Antibody
31%
Clinical Trial
30%
Diseases
29%
Bevacizumab
27%
Non-Hodgkin Lymphoma
24%
Low Drug Dose
23%
Awareness
22%
Diagnosis
22%
Low and Middle Income Countries
22%
Arm
21%
Cancer
20%
Iodine 131
20%
Metastatic Colorectal Cancer
20%
B Cell
20%
Adverse Event
19%
Triple Negative Breast Cancer
17%
Prevalence
16%
COVID-19
16%
Progression Free Survival
16%
Placebo
16%
Overall Survival
15%
Quality of Life
15%
CD20
14%
Antibody-Drug Conjugate
13%
Glembatumumab Vedotin
13%
Metastatic Melanoma
13%
Glycoprotein
13%
Tositumomab
13%
Veltuzumab
13%
Arsenic Trioxide
13%
Phase I Trials
13%
Solid Malignant Neoplasm
13%
Letrozole
13%
Postmenopause
13%
Carboplatin
13%
Gemcitabine
13%
Bendamustine
13%
Cancer Diagnosis
13%
Radiation Therapy
13%
Clinician
12%
Chemotherapy
11%
Infusion
11%
Immunoglobulin
11%
Receptor
11%
Immunology and Microbiology
Platelet
49%
Monoclonal Antibody
48%
Idiopathic Thrombocytopenic Purpura
35%
Immune Response
31%
Pharmacokinetics
29%
Intravenous Immunoglobulin
26%
Arm
23%
Antibody Response
23%
Immunity
21%
Glycoprotein
20%
Iodine-131
20%
Human Immunoglobulin
17%
T Cell
16%
Fc Receptor
15%
Rituximab
14%
Glembatumumab Vedotin
13%
Antibody Drug Conjugate
13%
Carcinoembryonic Antigen
13%
Edrecolomab
13%
Interferon Type I
13%
Thrombocyte Membrane
12%
Blood Plasma
12%
B Cell
11%
Maximum Tolerated Dose
10%
Platelet Count
10%
Interleukin 2 Receptor
10%
Blood Level
10%
Tumor Antigen
9%
CD20
9%
Chimeric Antibody
9%
Low Drug Dose
9%
CD16
9%
Plasma Half Life
8%
Immunoglobulin G4
8%
Biological Product
8%
Cyclophosphamide
8%
Immunoglobulin G1
8%
Lupus Erythematosus
8%
Immunoglobulin G
7%
Antigen Expression
7%
Antiidiotypic Antibody
6%
Tigatuzumab
6%
Veltuzumab
6%
Trastuzumab
6%
Etaracizumab
6%
Somatomedin
6%
Marginal Zone B-Cell
6%
Intravenous Immunoglobulin Therapy
6%
Death Receptor
6%
Prevotella
6%